{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:12:16Z","timestamp":1779286336150,"version":"3.51.4"},"reference-count":15,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers the possibility of reorganizing workflow, reducing the pressure on infusion units and improving the treatment experience for both patients and healthcare professionals. This study provides real-world evidence from a large public oncology hospital in Mexico City, examining how SC and IV trastuzumab compare in everyday practice with respect to treatment times, resources use and the perceptions of patients and staff.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A prospective time and motion study was conducted to compare the efficiency and operational impact of SC and IV routes of trastuzumab administered as monotherapy in women with HER2-positive breast cancer at a public hospital in Mexico City. Sixty administrations (30 SC and 30 IV) were analyzed, recorded in real time using a digital system specifically developed for this study. The system documented waiting times, preparation, administration and time spent in the treatment room. Resource utilization was estimated based on the average number of supplies required for each route. In addition, patients and healthcare personnel completed structured questionnaires on comfort, satisfaction and overall experience.\n                    <jats:bold>Results:<\/jats:bold>\n                    Treatment using the SC route was noticeably shorter. Compared with the IV route, median chair time and overall procedure duration dropped by close to 94%, and treatment room occupancy decreased by approximately 83%. This route also required fewer materials and avoided the drug loss due to weight-based IV dosing. Patients described the SC injection as more comfortable and less fatiguing, while healthcare professionals noted less physical effort, lower stress levels and a more manageable workflow.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In a routine public oncology setting with limited resources, the use of SC trastuzumab was associated with clear advantages in terms of efficiency and the treatment experience while also mitigating the workload of infusion areas. These results provide practical, context-specific evidence that could help healthcare systems to improve the organization of oncology services and make better use of scarce hospital resources.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0199","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:18:13Z","timestamp":1776680293000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-1476","authenticated-orcid":false,"given":"Tatiana","family":"Fiordelisio","sequence":"first","affiliation":[{"name":"Laboratorio Nacional de Soluciones Biomim\u00e9ticas para Diagn\u00f3stico y Terapia, Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-0666","authenticated-orcid":false,"given":"Francisco","family":"Vald\u00e9s-Souto","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-0866","authenticated-orcid":false,"given":"Diana del-Rio","family":"Valdes","sequence":"additional","affiliation":[{"name":"Laboratorio Nacional de Soluciones Biomim\u00e9ticas para Diagn\u00f3stico y Terapia, Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-5504","authenticated-orcid":false,"given":"Diego Zamarr\u00f3n","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Laboratorio Nacional de Soluciones Biomim\u00e9ticas para Diagn\u00f3stico y Terapia, Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-9467","authenticated-orcid":false,"given":"Karla Ram\u00edrez","family":"Pulido","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9688-0576","authenticated-orcid":false,"given":"Cristopher Alejandro","family":"Escamilla Soto","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9611-9888","authenticated-orcid":false,"given":"Yair Uriel","family":"Correa Trejo","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Itzel","family":"Guti\u00e9rrez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel Espino","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Alcald\u00eda Coyoac\u00e1n, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9860-3739","authenticated-orcid":false,"given":"Claudia Hayde\u00e9","family":"Arce Salinas","sequence":"additional","affiliation":[{"name":"Departamento de Oncolog\u00eda M\u00e9dica, Instituto Nacional de Cancerolog\u00eda (INCan), Alcald\u00eda Tlalpan, Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay J","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"e_1_3_9_4_2","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","author":"Stoner KL","year":"2014","unstructured":"Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient doi: 10.1007\/s40271-014-0075-y (2014) (Epub ahead of print).","journal-title":"Patient"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00361-3"},{"issue":"2","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1007\/s10875-012-9853-2","article-title":"Why I use subcutaneous immunoglobulin (SCIG)","volume":"33","author":"Shapiro RS","year":"2013","unstructured":"Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J. Clin. Immunol. 33(Suppl. 2), S95\u2013S98 (2013).","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2374373518770811","article-title":"Preference for subcutaneous injection or intravenous infusion of biological therapy among Italian patients with SLE","volume":"6","author":"Falanga M","year":"2019","unstructured":"Falanga M, Canzona A, Mazzoni D. Preference for subcutaneous injection or intravenous infusion of biological therapy among Italian patients with SLE. J. Patient Exp. 6(1), 41\u201345 (2019).","journal-title":"J. Patient Exp."},{"issue":"1","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"e0261336","DOI":"10.1371\/journal.pone.0261336","article-title":"Assessing the transition from intravenous to subcutaneous delivery of rituximab: benefits for payers, health care professionals, and patients with lymphoma","volume":"17","author":"Harvey MJ","year":"2022","unstructured":"Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Assessing the transition from intravenous to subcutaneous delivery of rituximab: benefits for payers, health care professionals, and patients with lymphoma. PLoS One 17(1), e0261336 (2022).","journal-title":"PLoS One"},{"issue":"6","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock E","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE 11(6), e0157957 (2016).","journal-title":"PLoS ONE"},{"issue":"3","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","volume":"5","author":"De Cock E","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 5(3), 389\u2013397 (2016).","journal-title":"Cancer Med."},{"issue":"3","key":"e_1_3_9_11_2","article-title":"Estado actual del c\u00e1ncer de mama en M\u00e9xico: principales tipos y factores de riesgo","volume":"20","author":"Arceo-Mart\u00ednez MT","year":"2021","unstructured":"Arceo-Mart\u00ednez MT, L\u00f3pez-Meza JE, Ochoa-Zarzosa A, Palomera-Sanchez Z. Estado actual del c\u00e1ncer de mama en M\u00e9xico: principales tipos y factores de riesgo. Gac. Mex. Oncol. 20(3), (2021).","journal-title":"Gac. Mex. Oncol."},{"key":"e_1_3_9_12_2","unstructured":"Instituto Nacional de Estad\u00edstica y Geograf\u00eda (INEGI). Estad\u00edsticas a prop\u00f3sito del D\u00eda Internacional de la lucha contra el c\u00e1ncer de mama (19 DE OCTUBRE). AguascalientesM\u00e9xico (2023). Available at: https:\/\/www.inegi.org.mx\/contenidos\/saladeprensa\/aproposito\/2023\/EAP_CMAMA23.pdf"},{"issue":"5","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner B","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs 32(5), 425\u2013440 (2018).","journal-title":"BioDrugs"},{"issue":"10","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot X","year":"2014","unstructured":"Pivot X, Gligorov J, M\u00fcller V Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann. Oncol. 25(10), 1979\u20131987 (2014).","journal-title":"Ann. Oncol."},{"issue":"6","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0035-1546172","article-title":"Subcutaneous trastuzumab for HER2-positive breast cancer \u2013 evidence and practical experience in 7 German centers","volume":"75","author":"Jackisch C","year":"2015","unstructured":"Jackisch C, M\u00fcller V, Dall P Subcutaneous trastuzumab for HER2-positive breast cancer \u2013 evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd. 75(6), 566\u2013573 (2015).","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"1","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4274\/ejbh.galenos.2021.2021-9-9","article-title":"An open-label, multinational, multicenter, Phase IIIb study with subcutaneous administration of trastuzumab in patients with HER2-positive early breast cancer to evaluate patient satisfaction","volume":"18","author":"Cicin \u0130","year":"2022","unstructured":"Cicin \u0130, Oukkal M, Mahfouf H An open-label, multinational, multicenter, Phase IIIb study with subcutaneous administration of trastuzumab in patients with HER2-positive early breast cancer to evaluate patient satisfaction. Eur. J. Breast Health 18(1), 63\u201373 (2022).","journal-title":"Eur. J. Breast Health"},{"issue":"12","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco G","year":"2017","unstructured":"Lopez-Vivanco G, Salvador J, Diez R Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin. Transl. Oncol. 19(12), 1454\u20131461 (2017).","journal-title":"Clin. Transl. Oncol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:52:39Z","timestamp":1779285159000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.57264\/cer-2025-0199"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0199","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"e250199"}}